TY  - CONF 
AU  - Taylor, P. C.
AU  - van de Laar, M.
AU  - Curtis, J. R.
AU  - Azevedo, V. F.
AU  - Rivas, J. L.
AU  - Dahl, P.
AU  - Wang, L.
AU  - Iikuni, N.
AU  - Shi, H.
AU  - Woolcott, J.
AU  - Benkhalifa, S.
AU  - Gómez-Reino Carnota, Juan Jesús
AU  - Dougados, M.
PY  - 2019
SN  - 0003-4967
UR  - http://hdl.handle.net/20.500.11940/15740
AB  - Background: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Pain is the most common symptom reported by patients (pts) with RA,1,2 thus reduction of pain is an important treatment goal.

Objectives: To evaluate the effect of...
LA  - eng
TI  - Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: a post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
DO  - 10.1136/annrheumdis-2019-eular.416
KW  - CHUS
VL  - 78
ER  -